Royalty Pharma shares rise 6.82% intraday after Q3 results show 11% growth in receipts and raised guidance.

Royalty Pharma surged 6.82% intraday following the release of its Q3 2025 results, which showed an 11% year-over-year increase in both Royalty and Portfolio Receipts driven by high-performing assets like Voranigo, Tremfya, and the cystic fibrosis franchise. The company raised full-year Portfolio Receipts guidance to $3.2–3.25 billion, reflecting strong demand for its royalty portfolio and recent capital deployments, including $1.0 billion in Q3 acquisitions of royalties on Amgen’s Imdelltra, Alnylam’s Amvuttra, and Zenas BioPharma’s obexelimab. These developments, coupled with positive clinical updates across its portfolio (e.g., Revolution Medicines’ daraxonrasib and Roche’s trontinemab), signaled robust growth momentum and reinforced investor confidence in Royalty Pharma’s ability to sustain compounding returns as a leading biopharma royalty capital allocator.